Published in Physiol Rev on January 01, 1993
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol (2000) 4.33
Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol (1994) 3.68
LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev (2008) 3.46
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol (1999) 2.93
Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development (1996) 2.88
Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J (1995) 2.38
Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J (1996) 2.36
Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci U S A (1997) 2.35
Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A (1995) 2.25
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol (2000) 2.05
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J (1997) 1.85
Expression of plasminogen activator pla of Yersinia pestis enhances bacterial attachment to the mammalian extracellular matrix. Infect Immun (1998) 1.76
A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. Biophys J (2007) 1.74
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer (1999) 1.71
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J (1996) 1.70
Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol (2001) 1.68
Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol (1994) 1.65
Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J Cell Biol (1996) 1.64
Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol (1998) 1.60
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol (2001) 1.57
Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell (2004) 1.57
A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol (1998) 1.51
Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther (2005) 1.49
Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J (1998) 1.48
Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. J Cell Biol (1997) 1.48
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis (1999) 1.46
The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs (2011) 1.41
Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A (1996) 1.39
Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res (1995) 1.37
Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci U S A (1994) 1.31
Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol (1995) 1.30
Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol (1997) 1.27
Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res (2010) 1.26
An old enzyme with a new function: purification and characterization of a distinct matrix-degrading metalloproteinase in rat kidney cortex and its identification as meprin. J Cell Biol (1994) 1.25
Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci (2011) 1.23
Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced G-protein and membrane-type matrix metalloproteinase-1-dependent signaling. Mol Cancer (2006) 1.22
Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease. J Clin Invest (1998) 1.21
Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol (2003) 1.21
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol (2005) 1.20
Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. Transl Oncol (2008) 1.17
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res (2004) 1.16
Plasmin-coated borrelia Burgdorferi degrades soluble and insoluble components of the mammalian extracellular matrix. Infect Immun (1999) 1.16
Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol (2003) 1.15
Bacterial plasminogen receptors: in vitro evidence for a role in degradation of the mammalian extracellular matrix. Infect Immun (1995) 1.12
Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br J Cancer (2001) 1.12
Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis (1998) 1.12
Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol (1999) 1.11
High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer (2009) 1.11
Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One (2011) 1.10
The mechanism for the activation of latent TGF-beta during co-culture of endothelial cells and smooth muscle cells: cell-type specific targeting of latent TGF-beta to smooth muscle cells. J Cell Biol (1993) 1.10
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer (1999) 1.10
Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis (2000) 1.09
A hybrid model for three-dimensional simulations of sprouting angiogenesis. Biophys J (2008) 1.09
Disruption of LTBP-4 function reduces TGF-beta activation and enhances BMP-4 signaling in the lung. J Cell Biol (2004) 1.09
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J (1994) 1.09
Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol (2002) 1.08
Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest (1995) 1.08
Extracellular matrix remodeling and the regulation of epithelial-stromal interactions during differentiation and involution. Kidney Int Suppl (1996) 1.07
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol (1994) 1.07
The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am J Pathol (2009) 1.07
Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol (2012) 1.05
Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br J Cancer (1998) 1.05
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol (2003) 1.05
Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer (1999) 1.04
Front instabilities and invasiveness of simulated avascular tumors. Bull Math Biol (2009) 1.02
Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol (2013) 1.02
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis (1999) 1.01
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer (1998) 1.01
The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin Dev Immunol (2013) 1.01
Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. Inflammation (1998) 1.01
Expression of matrix proteinases during human intrahepatic bile duct development. A possible role in biliary cell migration. Am J Pathol (1995) 1.00
Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase. Neoplasia (1999) 1.00
Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest (1999) 1.00
Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer (1996) 1.00
OspC is potent plasminogen receptor on surface of Borrelia burgdorferi. J Biol Chem (2012) 1.00
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis (2002) 1.00
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer (2001) 0.99
Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol (2005) 0.99
Molecular mediators of angiogenesis. J Burn Care Res (2010) 0.98
Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am J Pathol (1996) 0.96
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J (1999) 0.96
The role of nephritis-associated plasmin receptor (NAPlr) in glomerulonephritis associated with streptococcal infection. J Biomed Biotechnol (2012) 0.95
Nicotine enhances migration and invasion of human esophageal squamous carcinoma cells which is inhibited by nimesulide. World J Gastroenterol (2009) 0.94
Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis (1999) 0.94
A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther (2006) 0.94
Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer (1999) 0.94
Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers. Clin Exp Metastasis (2003) 0.94
Glutamine synthetase and glucose-6-phosphate isomerase are adhesive moonlighting proteins of Lactobacillus crispatus released by epithelial cathelicidin LL-37. J Bacteriol (2012) 0.94
Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int (2007) 0.93
The single substitution I259T, conserved in the plasminogen activator Pla of pandemic Yersinia pestis branches, enhances fibrinolytic activity. J Bacteriol (2009) 0.92
Tumor detection by imaging proteolytic activity. Cancer Res (2010) 0.92
Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? Br J Cancer (1998) 0.92
Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin Exp Metastasis (1998) 0.92
High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg (2007) 0.92
Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis (1998) 0.91
The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell (1999) 11.59
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem (1994) 6.31
An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J Exp Med (1973) 5.53
An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. II. Mammalian fibroblast cultures transformed by DNA and RNA tumor viruses. J Exp Med (1973) 4.99
Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol (1989) 4.57
Biological roles of fibroblast growth factor-2. Endocr Rev (1997) 3.57
Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell (1986) 3.42
Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol (1988) 3.16
Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol (1998) 3.12
Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol (1988) 2.84
Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int (1997) 2.82
Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol (1988) 2.69
Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol (1990) 2.65
Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc Natl Acad Sci U S A (1986) 2.62
Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol (1990) 2.33
Plasminogen activator and collagenase production by cultured capillary endothelial cells. J Cell Biol (1982) 2.33
Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A (1991) 2.27
Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1. Mol Biol Cell (1998) 2.26
Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol (1992) 2.08
In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol (1989) 2.05
The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol (1987) 2.04
Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol (1997) 1.98
Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol (1986) 1.94
TGF-beta latency: biological significance and mechanisms of activation. Stem Cells (1997) 1.91
Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol (1986) 1.91
Transformation of rat embryo fibroblasts by cloned polyoma virus DNA fragments containing only part of the early region. Proc Natl Acad Sci U S A (1980) 1.89
Properties of plasminogen activators formed by neoplastic human cell cultures. J Exp Med (1974) 1.88
Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta (1988) 1.82
Recombinant basic fibroblast growth factor stimulates wound healing in healing-impaired db/db mice. J Exp Med (1990) 1.80
Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol (1990) 1.75
Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J Cell Biol (1993) 1.71
Processing, secretion, and biological properties of a novel growth factor of the fibroblast growth factor family with oncogenic potential. Mol Cell Biol (1988) 1.69
A form of human basic fibroblast growth factor with an extended amino terminus. Biochem Biophys Res Commun (1987) 1.69
Proteolytically derived fragments of human plasma fibronectin and their localization within the intact molecule. J Biol Chem (1980) 1.68
Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol (1993) 1.66
Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res (1990) 1.59
Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem (1994) 1.58
A specific labeling procedure for proteins on the outer surface of membranes. J Biol Chem (1972) 1.55
Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc Natl Acad Sci U S A (1991) 1.52
Characterization of latent TGF-beta activation by murine peritoneal macrophages. J Immunol (1995) 1.52
Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity. J Cell Biol (1992) 1.51
Phospholipid composition of Rous sarcoma virus, host cell membranes and other enveloped RNA viruses. Virology (1971) 1.49
Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair. Lab Invest (1989) 1.48
Tumor promoters induce changes in the chick embryo fibroblast cytoskeleton. Cell (1979) 1.47
Requirement for the large T and small T proteins of SV40 in the maintenance of the transformed state. Cold Spring Harb Symp Quant Biol (1980) 1.43
Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J Cell Biol (1990) 1.42
Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc Natl Acad Sci U S A (1983) 1.42
Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein (1996) 1.42
Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci U S A (1990) 1.42
Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol (1989) 1.42
Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. J Biol Chem (1996) 1.40
Mr 25,000 heparin-binding protein from guinea pig brain is a high molecular weight form of basic fibroblast growth factor. Proc Natl Acad Sci U S A (1987) 1.39
Early mutants of polyoma virus (dl8 and dl23) with altered transformation properties: is polyoma virus middle T antigen a transforming gene product? Cold Spring Harb Symp Quant Biol (1980) 1.39
Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. J Cell Biol (1990) 1.37
Transformation of primary hamster brain cells with JC virus and its DNA. J Virol (1980) 1.36
Tetradecanoyl phorbol acetate stimulates latent collagenase production by cultured human endothelial cells. Cell (1980) 1.35
Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol (1994) 1.32
In vitro neurite extension by granule neurons is dependent upon astroglial-derived fibroblast growth factor. Dev Biol (1988) 1.32
FGF suppresses apoptosis and induces differentiation of fibre cells in the mouse lens. Development (1995) 1.31
Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell (1993) 1.31
Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol (1989) 1.30
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol (1999) 1.30
Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: possible intracellular signaling by the high molecular weight forms. J Cell Biol (1995) 1.30
High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proc Natl Acad Sci U S A (1993) 1.29
Selective lysis of cells transformed by Rous Sarcoma virus. Virology (1971) 1.29
The NH2-terminal extension of high molecular weight bFGF is a nuclear targeting signal. J Cell Physiol (1991) 1.29
Activation of latent transforming growth factor beta. Adv Pharmacol (1993) 1.26
The extracellular regulation of growth factor action. Mol Biol Cell (1992) 1.25
The organization of the proteins of vesicular stomatitis virions: labeling with pyridoxal phosphate. Virology (1975) 1.23
Extracellular microfibrils in development and disease. Cell Mol Life Sci (2007) 1.21
Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood (1993) 1.19
Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Curr Eye Res (1999) 1.14
The latent transforming growth factor-beta-binding protein-1 promotes in vitro differentiation of embryonic stem cells into endothelium. Mol Biol Cell (2000) 1.14
Transforming growth factor-beta 1 regulates axon/Schwann cell interactions. J Cell Biol (1995) 1.14
Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol (1991) 1.13
Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol (1992) 1.13
Methylation of high molecular weight fibroblast growth factor-2 determines post-translational increases in molecular weight and affects its intracellular distribution. Mol Biol Cell (1996) 1.12
Extracellular matrix regulation of growth factor and protease activity. Curr Opin Cell Biol (1991) 1.12
Production of plasminogen activator by established cell lines of mouse origin. J Cell Biol (1977) 1.11
Studies of Rous sarcoma virus. Effects of nucleoside analogues on virus synthesis. J Biol Chem (1973) 1.11
Bone defects in latent TGF-beta binding protein (Ltbp)-3 null mice; a role for Ltbp in TGF-beta presentation. J Endocrinol (2002) 1.10
Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J (1994) 1.10
Down-regulation of epidermal growth factor receptor correlates with plasminogen activator activity in human A431 epidermoid carcinoma cells. Proc Natl Acad Sci U S A (1983) 1.10
The development of a quantitative RIA for basic fibroblast growth factor using polyclonal antibodies against the 157 amino acid form of human bFGF. The identification of bFGF in adherent elicited murine peritoneal macrophages. J Immunol Methods (1988) 1.07
A wound healing model using healing-impaired diabetic mice. J Dermatol (1992) 1.07
Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol (1991) 1.07
Selective expression of high molecular weight basic fibroblast growth factor confers a unique phenotype to NIH 3T3 cells. Cell Regul (1991) 1.07
Biochemical analysis of the arginine methylation of high molecular weight fibroblast growth factor-2. J Biol Chem (2000) 1.07
Virus-induced modification of cellular membranes related to viral structure. Annu Rev Microbiol (1974) 1.06
Isolation of a protease inhibitor from tissues resistant to tumor invasion. Hoppe Seylers Z Physiol Chem (1977) 1.06
Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol (1991) 1.06
Transformation by basic fibroblast growth factor requires high levels of expression: comparison with transformation by hst/K-fgf. Oncogene Res (1989) 1.05
Isolation and characterization of ribonucleoprotein substructures from Rous sarcoma virus. Virology (1972) 1.05
The presence of two major hemoglobin components in an inbred strain of mice. Proc Natl Acad Sci U S A (1966) 1.04
Stimulation of motility in cultured bovine capillary endothelial cells by angiogenic preparations. J Cell Physiol (1984) 1.04
SV40 mutants with an altered small-t protein are tumorigenic in newborn hamsters. Virology (1981) 1.02
Lipid studies of Rous sarcoma virus and host cell membranes. Virology (1972) 1.02